Licensing · MENA · Announced 18 May 2023
Sunshine Lake Pharma → Julphar
Licensing deal between Sunshine Lake Pharma (China) and Julphar (United Arab Emirates), covering Insulin glargine, announced 18 May 2023. Value: Undisclosed.
Parties: Sunshine Lake Pharma (China) → Julphar (United Arab Emirates)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- MENA region
- Therapeutic area
- Metabolic / Diabetes
- Asset
- Insulin glargine (long-acting) + insulin aspart (short-acting) — insulin analogues / biosimilars
- Announced
- 18 May 2023
Our analysis
Why it matters
A regional first: localizing modern insulin. This is not a distribution licence; it's a tech-transfer to build MENA's first modern insulin-analogue manufacturing — glargine and aspart, covering long- and short-acting needs.
Julphar had already flagged (Oct 2022) its ambition to build the Middle East's first Glargine factory ; this deal supplies the product and know-how to do it. The demand case is stark: per the release, MENA has 73 million adults with diabetes (16.2% of adults) and a ~$33bn annual treatment cost, with the patient count expected to double in 20 years.
The full analysis is free to read with a work email on this page.
Source: Julphar News Letter